BRNS - Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc Logo

BRNS - Barinthus Biotherapeutics plc

https://www.barinthusbio.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company is headquartered in Harwell, the United Kingdom.

52W High
$2.91
52W Low
$0.64
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
-0.74
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-6.67
EV/Revenue (<3 favorable)
0.62
P/S (TTM) (<3 favorable)
3.37
P/B (<3 favorable)
0.49
Ownership
Balanced
Source: Overview
Insiders (1–5% typical)
13.65%
Institutions (25–75% balanced)
44.49%
Shares Outstanding
40,718,200
Float
35,677,300
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
14,969,000
Gross Profit (TTM)
14,439,000
EPS (TTM)
-1.73
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-3.61%
ROE (TTM) (>15% strong)
-0.54%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
-0.0430
Previous
-0.0374
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025